From pain generator to analgesic platform: is the chest tube part of the solution after video- or robotic assisted thoracoscopic surgery?

Video- or robotic-assisted thoracoscopic surgery (VATS/RATS) has substantially reduced surgical trauma compared with open thoracotomy, but postoperative pain remains a clinically relevant challenge (1-3). While attention has traditionally focused on the surgical incisions and intercostal nerve injury, the chest drain itself is increasingly recognized as an important contributor to postoperative discomfort (4). Its position within an innervated intercostal space, continuous irritation of the parietal pleura, and pain during mobilization, coughing, and deep breathing may compromise recovery even after otherwise minimally invasive surgery.

Against this background, the concept evaluated in the present randomized trial is both simple and appealing: if the chest tube contributes to pain, could it simultaneously become a route for its treatment (5)?

The authors investigated a drainage-analgesia integrated (DAI) chest tube that combines conventional pleural drainage with localized delivery of local anesthetic. In 47 patients undergoing VATS, use of the DAI system was associated with lower pain scores at 24 and 48 hours, fewer patient-controlled analgesia (PCA) activation attempts, and higher Quality of Recovery-15 (QoR-15) scores at 48 hours compared with conventional chest drainage. Importantly, these benefits were achieved without placement of an additional regional analgesia catheter and without reported device-related complications.

The attraction of this approach lies primarily in its simplicity. Contemporary thoracic anesthesia increasingly emphasizes multimodal and opioid-sparing analgesia as part of enhanced recovery after thoracic surgery (ERATS) pathways (6). Several regional techniques are available, including thoracic epidural analgesia, paravertebral block, erector spinae plane block, serratus anterior plane block, and intercostal nerve blockade. Each has specific advantages, but each also requires additional procedures, expertise, equipment, or catheter management.

The DAI concept takes a different approach, rather than adding another invasive procedure. It uses a device that is already required for many patients undergoing pulmonary resection. This represents an attractive principle of perioperative care: integration rather than escalation.

Localized intrapleural administration of local anesthetics may also address an important component of post-VATS/RATS pain close to its anatomical origin. Chest drains can irritate both the intercostal structures at their insertion site and the highly sensitive parietal pleura. Local anesthetic delivery through the drainage system therefore has a plausible mechanistic rationale, particularly during the early postoperative period when the drain remains in place.

Less pain-but is it truly opioid-sparing? The findings nevertheless require careful interpretation. Although pain scores and PCA activation frequency were reduced, total sufentanil consumption did not differ significantly between groups. This distinction is important. A reduction in pain intensity does not necessarily translate into a clinically meaningful opioid-sparing effect, particularly when both groups receive PCA with a continuous background opioid infusion. Such a regimen may reduce the ability to demonstrate differences in patient-driven opioid requirements because a substantial proportion of opioid exposure is predetermined and independent of pain intensity.

The lower number of PCA activation attempts in the DAI group may therefore be particularly informative. It suggests that patients perceived less need for rescue analgesia, even though this difference was not reflected in cumulative sufentanil consumption. Future studies using demand-only PCA or a more explicitly opioid-sparing multimodal regimen might better determine whether DAI analgesia can meaningfully reduce postoperative opioid exposure.

The magnitude of the observed differences in pain scores also deserves attention. Statistical significance alone should not define the value of a new analgesic intervention. Whether the reduction in Visual Analogue Scale (VAS) scores reaches a clinically important threshold - and whether this translates into better coughing, mobilization, respiratory function, sleep, or earlier readiness for discharge - will ultimately determine its relevance for enhanced recovery pathways.

The patient-centered recovery may matter more than pain scores alone. Perhaps one of the more interesting observations is the improvement in QoR-15 at 48 hours. Modern perioperative analgesia should not be judged exclusively by pain scores or opioid consumption. Pain is one component of a broader recovery process encompassing physical comfort, emotional well-being, functional independence, and the ability to mobilize and participate in postoperative rehabilitation. This is particularly relevant after thoracic surgery. Effective analgesia is not an end in itself; its purpose is to facilitate deep breathing, coughing, mobilization, and restoration of function while minimizing opioid-related adverse effects. The observed improvement in QoR-15 therefore supports a patient-centered interpretation of the intervention. However, the magnitude and clinical relevance of this difference should be confirmed in adequately powered trials.

The data from the study show promising results, but these have not yet led to any changes in practice. Several limitations should temper enthusiasm. The study included only 47 patients, was conducted at a single center, and was open-label. Lack of blinding is particularly relevant when the primary endpoint is a patient-reported pain score and when secondary outcomes include PCA activation and quality-of-recovery assessments. Both patients’ expectations and clinicians’ behavior may influence these outcomes. The small sample size also limits conclusions regarding safety. The absence of device-related complications in 22 patients receiving the DAI chest tube is reassuring but cannot establish safety for broader clinical use. Potential issues such as local anesthetic systemic toxicity, catheter malfunction, interference with drainage, infection, dosing errors, or uneven intrapleural distribution will require evaluation in substantially larger populations. Furthermore, intrapleural delivery of local anesthetic is not a completely new analgesic principle. The novelty lies primarily in integrating analgesic delivery into the drainage device itself. Future investigations should therefore establish not only superiority over conventional chest drainage but also the comparative effectiveness of this strategy against contemporary regional analgesic approaches.

The question is, what direction should research take next? The present study should be regarded as an encouraging proof of concept rather than definitive evidence for a change in practice. A larger, preferably multicenter and assessor-blinded trial should evaluate the intervention within a contemporary ERATS pathway and include clinically meaningful outcomes beyond static pain scores.

Such studies should examine dynamic pain during coughing and mobilization, opioid consumption without a continuous PCA background infusion, pulmonary function, postoperative nausea and vomiting, time to mobilization, chest tube duration, length of stay, QoR-15, and complications related to both the device and local anesthetic administration. Dose, concentration, administration interval, and pharmacokinetics of the local anesthetic also require systematic evaluation.

Equally important will be identifying which patients benefit most. The value of an integrated analgesic chest tube may differ according to the extent of pulmonary resection, number and size of ports, number of chest drains, duration of drainage, baseline opioid exposure, and the regional analgesic technique otherwise used.

From necessary drain to therapeutic platform

The most compelling aspect of this study may ultimately be conceptual rather than numerical. Thoracic anesthesia has progressively moved from highly invasive analgesic techniques toward individualized, multimodal, and procedure-specific strategies. Transforming a necessary postoperative device into a vehicle for targeted analgesia fits well within this evolution.

The DAI chest tube will not eliminate the need for multimodal analgesia, nor do the present data establish it as an alternative to established regional techniques. However, the study raises an intriguing possibility: rather than accepting the chest drain solely as an unavoidable source of postoperative pain, we may be able to use it as part of the solution.

For now, the concept is promising, pragmatic, and worthy of further investigation. Whether integrated chest tube analgesia can ultimately deliver clinically meaningful opioid reduction, accelerate functional recovery, and simplify ERATS pathways remains to be demonstrated in larger trials. If it can, turning a pain-generating device into an analgesic platform would represent an elegant example of how small innovations can meaningfully reshape perioperative care.

Supplementary

The article’s supplementary files as

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.